Hunter Syndrome (MPS II) Market to Reach USD 2.48 Billion by 2034

Pune, India - December 2025 - The global Hunter Syndrome Market, valued at USD 1.54 billion in 2024, is projected to reach USD 2.48 billion by 2034, growing at a 4.9% CAGR (2025-2034), according to Exactitude Consultancy. Rising awareness of lysosomal storage disorders (LSDs), increased access to enzyme replacement therapy (ERT), and promising developments in gene therapy are driving market expansion.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71991

Market Summary
The Hunter Syndrome Market is evolving steadily as improved genetic screening and rare disease awareness enhance early diagnosis of MPS II-a rare X-linked lysosomal storage disorder caused by iduronate-2-sulfatase (IDS) deficiency. Accumulation of glycosaminoglycans (GAGs) leads to progressive multi-organ involvement, including developmental delays, airway obstruction, joint stiffness, cardiac complications, and reduced life expectancy in severe cases.

Current treatment is centered around enzyme replacement therapy (ERT), primarily idursulfase, which remains the standard of care for managing somatic symptoms. Research interest is accelerating in gene therapy, substrate reduction therapy (SRT), novel ERT formulations, and brain-penetrating biologics aimed at treating the neurological form of the disease-a critical unmet need. Increased adoption of newborn screening, whole-exome sequencing, biomarker assays, and multidisciplinary care is expanding the documented patient pool globally.

North America and Europe dominate due to high diagnostic and treatment accessibility, while Asia-Pacific is the fastest-growing region, driven by improved healthcare infrastructure and expanding genetic testing penetration.

Key Takeaways
• 2024 Market Size: USD 1.54 Billion
• 2034 Forecast: USD 2.48 Billion
• CAGR: 4.9% (2025-2034)
• ERT remains the primary treatment; gene therapy is the future growth engine
• Expanded newborn and genetic screening improving early detection
• Asia-Pacific experiencing rapid increase in diagnosed cases

Market Drivers
• Advancements in enzyme replacement & next-gen therapeutic pipelines
• Improved rare disease diagnosis through genetic testing
• Increased government and NGO support for LSD treatment programs
• Growth in newborn screening adoption in emerging markets
• Rising clinical trial activity targeting CNS involvement

Segmentation Snapshot
By Disease Type
• Attenuated Hunter Syndrome
• Severe Neurological Hunter Syndrome

By Treatment Type
• Enzyme Replacement Therapy (ERT - Idursulfase)
• Hematopoietic Stem Cell Transplantation (HSCT)
• Gene Therapy (AAV-based, emerging)
• Substrate Reduction Therapy (SRT)
• Supportive & Symptomatic Care

By Diagnostic Method
• Genetic Testing (IDS Gene Mutation Analysis)
• Enzyme Activity Assays
• Urinary GAG Testing
• Newborn Screening
• Clinical Evaluation

By End User
• Hospitals
• Metabolic & Rare Disease Specialty Centers
• Pediatric Clinics
• Genetic Testing Laboratories
• Research Institutes

By Region
• North America (Largest Market)
• Europe
• Asia-Pacific (Fastest Growing)
• Latin America
• Middle East & Africa

Explore Full Report here: https://exactitudeconsultancy.com/reports/71991/hunter-syndrome-market

Recent Developments
• Advancements in CNS-targeted gene therapy entering clinical evaluation.
• Improved ERT formulations designed for enhanced tissue penetration.
• Expansion of national newborn screening programs for LSDs.
• Growing research collaborations to accelerate rare disease drug development.

Expert Quote - Irfan Tamboli, Business Development Executive
"Hunter Syndrome treatment is undergoing a transformative shift with gene therapy leading the next wave of innovation. As diagnostics improve and global access to ERT expands, the documented patient pool is increasing steadily."

Conclusion
The Hunter Syndrome Market will continue to expand through 2034 as genetic testing improves, therapeutic innovation accelerates, and healthcare systems strengthen support for rare metabolic disorders. Companies investing in gene therapy platforms, advanced ERT, and integrated rare disease care models will drive the next phase of market growth.

This report is also available in the following languages : Japanese (ハンター症候群市場), Korean (헌터 증후군 시장), Chinese (亨特综合症市场), French (Marché du syndrome de Hunter), German (Markt für Jäger-Syndrom), and Italian (Mercato della sindrome di Hunter), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @https://exactitudeconsultancy.com/request-sample/71991

Related Reports

Cardiac Ablation Market
https://exactitudeconsultancy.com/reports/75570/cardiac-ablation-market

Osteoporosis and Prader-Will Syndrome (PWS) Market
https://exactitudeconsultancy.com/reports/75823/osteoporosis-and-prader-will-syndrome-pws-market

Acute Radiation Syndrome Market
https://exactitudeconsultancy.com/reports/76062/acute-radiation-syndrome-market

Pulmonary Surfactant Market
https://exactitudeconsultancy.com/reports/76083/pulmonary-surfactant-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.